SCHEMBL14720181

SCHEMBL14720181

COC(=O)C1CC(=O)/C(=C/N(C)C)C1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
GAA P10253 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KMT2A Q03164 3/20 0.43
F2 P00734 3/20 0.41
F10 P00742 1/20 0.41
BRD4 O60885 1/20 0.40
BUB1 O43683 2/20 0.37
MAP1LC3B Q9GZQ8 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
CHRNB2 P17787 2/20 0.33
CHRNA4 P43681 2/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA7 P36544 1/20 0.33
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14720183 1.00 MAPT (0.44) MAPTGAANPSR1KMT2AF2
SCHEMBL23284252 1.00 MAPT (0.44) MAPTGAANPSR1KMT2AF2
SCHEMBL10243813 0.86 MAPT (0.42) MAPTGAANPSR1KMT2AF2
SCHEMBL23276872 0.86 MAPT (0.42) MAPTGAANPSR1KMT2AF2
SCHEMBL23277064 0.86 MAPT (0.42) MAPTGAANPSR1KMT2AF2
SCHEMBL23276873 0.86 MAPT (0.42) MAPTGAANPSR1KMT2AF2
SCHEMBL23277063 0.86 MAPT (0.42) MAPTGAANPSR1KMT2AF2
SCHEMBL25554175 0.83 ALDH1A1 (0.46) MAPTGAAKMT2AALDH1A1MEN1
SCHEMBL29226651 0.81 MAP1LC3B (0.40) MAPTGAANPSR1KMT2AF2
SCHEMBL30234127 0.74 ALDH1A1 (0.39) MAPTKMT2AALDH1A1MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2744499-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2016-09-28 EP disclosed
US-9062070-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2015-06-23 US disclosed
US-20140206618-A1 Inhibitors of the Renal Outer Medullary Potassium Channel MERCK SHARP & DOHME LLC 2014-07-24 US disclosed
EP-2744499-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL Merck Sharp & Dohme Corp. (US) 2014-06-25 EP disclosed
WO-2013028474-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206618-A1 Inhibitors of the Renal Outer Medullary Potassium Channel KCNJ11, KCNJ1, KCNJ2 MAPT 4334/4885GAA 3563/4885NPSR1 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.